News | June 01, 2015

Siemens’ Imaging Guides Selective Internal Radiation Therapy Solution for Liver Cancer

Siemens collaborating with Australia-based Sirtex Medical Ltd. to deliver effective oncology treatments using novel small particle technology

Siemens, Sirtex Medical Ltd., SIRT, Yttrim-90, Y-90, Artis, liver cancer

June 1, 2015 — At the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago, Siemens presented advanced imaging solutions for Selective Internal Radiation Therapy (SIRT), an innovative therapy procedure for inoperable liver cancers. Siemens and collaborating company Sirtex Medical Ltd. demonstrated the solution and jointly hosted an Industry Expert Theater session on the topic at the 2015 ASCO annual meeting, May 29-June 2.  

Clinically advanced primary or secondary liver tumors, which are not candidates for resection, often have a limited prognosis. Over the past years, interventional procedures such as SIRT, also known as radioembolization, started to play a more meaningful role in the treatment of these tumors. However, the application of such effective local therapies was limited to experienced centers in order to reduce the risks of treatment-related complications that can occur if targeted therapies are inadvertently applied outside the target organ. More recently, with the introduction of advanced imaging technology such as Siemens’ Artis angiography systems, the safety of application could be further improved due to advanced image guidance. SIRT treats liver cancer internally by injecting millions of tiny radioactive microspheres (developed by Sirtex Medical Ltd.) directly into the tumors. The microspheres, extremely small resin beads containing radioactive Yttrim-90 (Y-90), become lodged in blood vessels inside the tumor, sparing the healthy tissue that surrounds it since the blood supply to the tumors is separate from that of the normal liver.

The technical execution of SIRT relies on angiographic imaging guidance. From pre-procedure planning to intra-procedure monitoring and control to post-procedure assessment, imaging plays a crucial role in the implementation of these treatments. Sufficient image quality is necessary to visualize the tumor, the application catheter within the feeding vessels, and surrounding structures during therapy.

Sirtex, a global healthcare business based in Australia focusing on oncology, has pioneered the SIRT procedure through development of the SIR-Spheres Y-90 resin microspheres used to deliver targeted internal radiation therapy directly to liver tumors via the hepatic artery.

For more information: www.siemens.com

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.